Search

Author/Creator Jaffe, A.

2. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Issue 9 (16th September 2016)

Authors:
Gibson, P. G.; Reddel, H.; McDonald, V. M.; Marks, G.; Jenkins, C.; Gillman, A.; Upham, J.; Sutherland, M.; Rimmer, J.; Thien, F.; Katsoulotos, G. P.; Cook, M.; Yang, I.; Katelaris, C.; Bowler, S.; Langton, D.; Robinson, P.; Wright, C.; Yozghatlian, V.; Burgess, S.
Journal:
Internal medicine journal
Issue:
Volume 46:Issue 9(2016)
Page Start:
1054
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Real‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Issue 11 (22nd July 2016)

Authors:
Hew, M.; Gillman, A.; Sutherland, M.; Wark, P.; Bowden, J.; Guo, M.; Reddel, H. K.; Jenkins, C.; Marks, G. B.; Thien, F.; Rimmer, J.; Katsoulotos, G. P.; Cook, M.; Yang, I.; Katelaris, C.; Bowler, S.; Langton, D.; Wright, C.; Bint, M.; Yozghatlian, V.
Journal:
Clinical & experimental allergy
Issue:
Volume 46:Issue 11(2016:Nov.)
Page Start:
1407
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗